Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 4/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3456405 | 0.85 | ACACB (0.44) | ACACBPPARGPPARAMRGPRX4FFAR1 | |
| SCHEMBL3455724 | 0.83 | ACACB (0.48) | ACACBPPARGPPARAMRGPRX4FFAR1 | |
| SCHEMBL7757972 | 0.82 | ACACB (0.42) | ACACBPPARGPPARAMRGPRX4FFAR1 | |
| SCHEMBL1568367 | 0.81 | DAO (0.53) | PPARGPPARAMRGPRX4DAODRD1 | |
| SCHEMBL7758227 | 0.81 | ACACB (0.44) | ACACBPPARGPPARAMRGPRX4FFAR1 | |
| SCHEMBL13016927 | 0.81 | ACACB (0.44) | ACACBPPARGPPARAMRGPRX4FFAR1 | |
| SCHEMBL3456499 | 0.81 | BACE1 (0.47) | ACACBPPARGPPARAMRGPRX4FFAR1 | |
| SCHEMBL8367734 | 0.80 | DRD1 (0.52) | PPARGPPARAMRGPRX4DAODRD1 | |
| SCHEMBL13016495 | 0.80 | BACE1 (0.48) | ACACBPPARGPPARAMRGPRX4PTGES | |
| SCHEMBL7754880 | 0.80 | BACE1 (0.48) | ACACBPPARGPPARAMRGPRX4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2256107-A1 | Amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone compounds as inhibitors of the beta-secretase (BACE) | Wyeth LLC (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20090012139-A1 | AMINO-5-[4-(DIFLUOROMETHOXY) PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF BETA-SECRETASE | WYETH (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012139-A1 | AMINO-5-[4-(DIFLUOROMETHOXY) PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF BETA-SECRETASE | WYETH (US) | 2009-01-08 | — | — | US | disclosed |
| US-7423158-B2 | Amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of β-secretase | WYETH (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423158-B2 | Amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of β-secretase | WYETH (US) | 2008-09-09 | — | — | US | disclosed |
| EP-1928841-A1 | AMINO-5- Ý4- (DIFLUOROMETHOXY) PHENYL¨-5-PHENYLIMIDAZOLONE COMPOUNDS AS INHIBITORS OF THE BETA-SECRETASE (BACE) | Wyeth a Corporation of the State of Delaware (US) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007038271-A9 | AMINO-5- [4- (DIFLUOROMETHOXY) PHENYL] -5-PHENYLIMIDAZOLONE COMPOUNDS AS INHIBITORS OF THE BETA-SECRETASE (BACE) | WYETH CORP (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2007038271-A1 | AMINO-5- [4- (DIFLUOROMETHOXY) PHENYL] -5-PHENYLIMIDAZOLONE COMPOUNDS AS INHIBITORS OF THE BETA-SECRETASE (BACE) | WYETH (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20070072925-A1 | Amino-5-[4-(difluoromehtoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of beta-secretase | WYETH (US) | 2007-03-29 | — | — | US | disclosed |
| US-20070072925-A1 | Amino-5-[4-(difluoromehtoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of beta-secretase | WYETH (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012139-A1 | AMINO-5-[4-(DIFLUOROMETHOXY) PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF BETA-SECRETASE | BACE1, BACE2, APP | ACACB 688/4885PPARG 3463/4885PPARA 3588/4885 |
| US-20070072925-A1 | Amino-5-[4-(difluoromehtoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of beta-secretase | BACE1, BACE2, APP | ACACB 594/4885PPARG 3304/4885PPARA 3481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.